New U.S. law requires better labeling on prescription drugs
美國新法要求改善處方藥標籤說明
A new piece of legislation called the "[CLEAR LABELS Act|noun]" has been introduced in the U.S.
一項名為「CLEAR LABELS法案」的新法案已在美國參議院提出。
Senate.
該法案旨在透過要求處方藥標籤明確列出最終藥物及其「原料藥」(APIs)的「原產國」來提高透明度。
This bill aims to improve transparency by requiring prescription drug labels to clearly list the "country of origin" for both the final medication and its "[Active Pharmaceutical Ingredients|noun]" (APIs).
目前，許多標籤僅顯示最終經銷商，導致患者和醫生難以追蹤藥物的實際生產地。
While the "[FDA|organization]" supports increased supply chain transparency, some industry groups worry about the high costs and logistical burdens this might create for manufacturers.
與目前側重於安全說明和劑量的法規不同，該法案專門針對「地緣政治和製造來源」資訊。
Unlike current regulations, which focus on safety instructions and dosage, this act specifically targets "[geopolitical and manufacturing source|noun]" information.
支持者希望這種增加的透明度將有助於確保為所有美國人提供一個更安全、更負責任的製藥市場。
